The Enterobacteriaceae are a family of Gram-negative bacteria that include commensal organisms as well as primary and opportunistic pathogens that are among the leading causes of morbidity and mortality worldwide. Although Enterobacteriaceae often comprise less than 1% of a healthy intestine's microbiota 1 , some of these organisms can bloom in the inflamed gut 2-5 ; expansion of enterobacteria is a hallmark of microbial imbalance known as dysbiosis 6 . Microcins are small secreted proteins that possess antimicrobial activity in vitro 7,8 , but whose role in vivo has been unclear. Here we demonstrate that microcins enable the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to limit the expansion of competing Enterobacteriaceae (including pathogens and pathobionts) during intestinal inflammation. Microcin-producing EcN limits the growth of competitors in the inflamed intestine, including commensal E. coli, adherent-invasive E. coli and the related pathogen Salmonella enterica. Moreover, only therapeutic administration of the wild-type, microcin-producing EcN to mice previously infected with S. enterica substantially reduced intestinal colonization by the pathogen. Our work provides the first evidence that microcins mediate inter-and intraspecies competition among the Enterobacteriaceae in the inflamed gut. Moreover, we show that microcins can act as narrow-spectrum therapeutics to inhibit enteric pathogens and reduce enterobacterial blooms.
The Enterobacteriaceae are a family of Gram-negative bacteria that include commensal organisms as well as primary and opportunistic pathogens that are among the leading causes of morbidity and mortality worldwide. Although Enterobacteriaceae often comprise less than 1% of a healthy intestine's microbiota 1 , some of these organisms can bloom in the inflamed gut 2-5 ; expansion of enterobacteria is a hallmark of microbial imbalance known as dysbiosis 6 . Microcins are small secreted proteins that possess antimicrobial activity in vitro 7, 8 , but whose role in vivo has been unclear. Here we demonstrate that microcins enable the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to limit the expansion of competing Enterobacteriaceae (including pathogens and pathobionts) during intestinal inflammation. Microcin-producing EcN limits the growth of competitors in the inflamed intestine, including commensal E. coli, adherent-invasive E. coli and the related pathogen Salmonella enterica. Moreover, only therapeutic administration of the wild-type, microcin-producing EcN to mice previously infected with S. enterica substantially reduced intestinal colonization by the pathogen. Our work provides the first evidence that microcins mediate inter-and intraspecies competition among the Enterobacteriaceae in the inflamed gut. Moreover, we show that microcins can act as narrow-spectrum therapeutics to inhibit enteric pathogens and reduce enterobacterial blooms.
Broad-spectrum antibiotics are largely unsuccessful in treating enterobacterial gut infections. Efforts to identify novel therapeutic treatments can be aided by identifying the mechanisms employed by beneficial microbes to mediate colonization resistance to pathogens 9, 10 . Reports of microcin-producing Enterobacteriaceae in human stool led to suggestions that microcins contribute to gut microbial ecology 11 . We therefore sought to identify an in vivo role for microcins by studying EcN 12, 13 and its interplay with related competitors in the gut. Microcins can exhibit potent antibacterial activity in vitro, similar to bacteriocins produced by Gram-positive bacteria [14] [15] [16] . In contrast to bacteriocins 15 , however, a compelling in vivo role for microcins has not previously been demonstrated 17 .
The EcN microcin gene cluster resides on genomic island I (Extended Data Fig. 1a and Supplementary Table 1 ) and encodes for microcin M (mcmA), microcin H47 (mchB) and their cognate immunity genes (mcmI and mchI, respectively). To understand whether the microcins of EcN promote colonization of the healthy intestine, we intragastrically inoculated specific-pathogen-free (SPF) mice with an equal mixture of a mouse-commensal E. coli (cEc) strain 18 and either wild-type EcN or a mutant unable to secrete both microcins (EcN mchDEF; all strains are described in Supplementary Table 3) 14 . Although all strains poorly and transiently colonized the healthy intestine (enterobacteria typically colonize at low levels in this setting), cEc colonization was not significantly impacted by either wild-type EcN or EcN mchDEF, and cEc outcompeted both strains to a similar extent (Extended Data Fig. 1b-g) .
To determine whether low colonization masked a microcin phenotype, we performed similar studies in germ-free mice and in streptomycintreated SPF mice. We administered cEc alone or in competition with wild-type EcN, EcN mchDEF, or EcN mcmA mchB, a mutant that lacks both microcin genes. All strains colonized the gut to high levels in these models, but cEc colonization was again unaffected by competition with EcN wild-type or microcin mutants ( Fig. 1a, b ). Moreover, there were no significant differences in colonization among EcN strains ( Fig. 1c, d ), and cEc outcompeted EcN wild-type and microcin mutants to a similar extent ( Fig. 1e , f). Together, these results indicate that the microcins of EcN do not provide a competitive advantage under homeostatic conditions ( Fig. 1g) .
Prior work has shown that the microcins of EcN possess antibacterial activity in iron-limited medium 14 . Moreover, a subset of microcins are post-translationally modified at the C terminus with a siderophore moiety [19] [20] [21] and EcN microcins are thought to be modified by a similar mechanism 14, 21 . In response to iron starvation, some commensals and pathogens synthesize and secrete siderophores to acquire this essential metal nutrient 22 . Bacterial uptake of iron-bound siderophores occurs via specific membrane receptors 14 . Microcins conjugated to siderophores are also synthesized during iron starvation and can target non-immune bacteria in vitro through cognate siderophore receptors 14, 16 , a mechanism described as a 'Trojan horse' mode of action 7 . Incorporating these observations, we proposed that microcins contribute to competition among enterobacteria in the inflamed gut, where iron is limited 23 .
We confirmed that EcN microcin genes (mcmA, mchB) are expressed in iron-limited medium, and not in iron-rich medium ( Fig. 1h ). To identify a role for microcins during intestinal inflammation, we used the dextran sulphate sodium (DSS)-treated mouse model of colitis ( Fig. 2a ). First, we inoculated DSS-treated SPF mice intragastrically with an equal mixture of cEc and either wild-type EcN, EcN mchDEF, or EcN mcmA mchB. Although cEc initially outcompeted (~ 10-fold) wild-type EcN, both strains colonized the intestine equally well by 5 days after inoculation. By contrast, cEc greatly outcompeted the microcin mutants (up to 10,000-fold; Fig. 2b and Extended Data Fig. 2a ). Whereas intestinal colonization of cEc was similar when alone or in competition with wild-type EcN or a microcin mutant at day 1-3 following inoculation, only wild-type EcN significantly reduced cEc colonization at later time points ( Fig. 2c and Extended Data Fig. 2b, h) . Consistent with this, the in vitro killing of cEc was only observed in iron-limited medium when competing with wild-type EcN, not the microcin mutants (Extended Data Fig. 3a-d ). As the EcN microcin mutants still express cognate microcin immunity proteins, their competitive growth in vitro was not impaired (Extended Data Fig. 3c -g) until the immunity genes were deleted (Extended Data Fig. 3h , i). Nevertheless, gut colonization of microcin mutants was similarly reduced in competition with cEc ( Fig. 2d and Extended Data Fig. 2c , i), but complementation of EcN mchDEF with mchDEF (EcN mchDEF pWSK29::mchDEF) restored colonization ( Fig. 2b-d ). As cEc was isolated from the murine gut, cEc is plausibly better adapted to growth in this environment than is EcN, a human isolate. Microcins thus give EcN a means by which to compete.
Colonization of microcin mutants was not impaired in DSS-treated mice when strains were administered alone or in competition with wild-type EcN, in contrast to competition with cEc ( Fig. 3a -c and Extended Data Fig. 4a-d) . Microcin mutants exhibited a 5-10-fold advantage over wild-type EcN at day 5 after inoculation ( Fig. 3c ). This observation may result from the mutants not having to expend energy on microcin production, yet still being immune to microcin activity; relatedly, wild-type EcN rescued the colonization of microcin mutants when co-administered with cEc in DSS-treated mice (Extended Data Fig. 4e -h). Microcin mutants are thus not intrinsically attenuated. Moreover, our findings indicate that microcins enable EcN to limit the expansion of a related commensal in the inflamed gut (Extended Data Fig. 2d -g), where Enterobacteriaceae thrive but also compete with each other for space and limited nutrients (niche competition).
We next tested whether iron supplementation during colitis inhibited microcin activity. Mice fed an iron-rich diet three weeks before and during DSS treatment developed colitis, yet wild-type EcN did not reduce colonization of cEc. Instead, both wild-type EcN and EcN mchDEF were outcompeted by cEc and exhibited similar levels of gut colonization (Extended data Fig. 5a-e ). Thus, if iron is supplemented, microcins do not limit the expansion of a competitor in the inflamed gut, probably because microcins, siderophores and siderophore receptors (that is, microcin receptors) are only expressed during iron starvation 14, 23 . These observations also suggest that, in contrast to broad-spectrum antibiotics, siderophore-linked microcins would have a limited effect on the gut microbiota as they only target strains that acquire those siderophores.
As microcins mediated competition between EcN and cEc in the DSS-colitis model, we analysed the intestinal microbiota in this setting. DSS treatment reduced the gut microbiota's diversity (Extended Data Fig. 5f ) and the subsequent administration of wild-type EcN or EcN mchDEF yielded similar shifts in microbial communities (Extended Data Fig. 5f , g and Supplementary Table 2 ). These results indicate that, at least in our DSS-treated mice, EcN microcins did not substantially change the gut microbiota, which is consistent with their predicted narrow spectrum.
In addition to some commensal Enterobacteriaceae, some enterobacterial pathogens thrive in the inflamed gut 3 . We therefore investigated microcin activity against the diarrheal pathogen Salmonella enterica serovar Typhimurium (STm). We first established that wild-type Fig. 6a-e ). When streptomycintreated mice (a Salmonella colitis model) were co-administered STm and either wild-type EcN or EcN mchDEF, only wild-type EcN outcompeted STm beyond day 4 after infection ( Fig. 3d, e ). Although all strains initially colonized the gut to similar levels, reduction of STm colonization was significantly enhanced by microcin-producing EcN (Fig. 3f ). By day 7, wild-type EcN and EcN mchDEF had similarly reduced STm colonization, probably because EcN has other mechanisms to outcompete STm, including a greater ability to acquire iron 23 . Nevertheless, in agreement with our cEc results ( Fig. 2a-d ), gut colonization of EcN mchDEF was drastically reduced in competition with STm 7 days after co-administration ( Fig. 3g ). Moreover, wild-type EcN's competitive advantage over STm was again only observed during intestinal inflammation (Extended Data Fig. 7a, b) . Relatedly, wild-type EcN and EcN mchDEF exhibited similar levels of intestinal colonization and no competitive advantages when competed with STm invA spiB, a mutant in both type-three secretion systems that is unable to trigger gut inflammation as it cannot invade the intestinal epithelium or replicate intracellularly (Extended Data Fig. 7c-e ).
Consistent with our results from STm and cEc experiments, microcins impaired growth of adherent invasive E. coli (AIEC), a pathobiont frequently isolated from patients with Crohn's disease. Wild-type EcN (but not EcN mchDEF) was able to reduce AIEC growth in vitro (Extended Data Fig. 6f -i) and in the DSS-colitis model (Extended Data Fig. 8 ). Although AIEC and wild-type EcN colonized the inflamed gut to similar levels, AIEC significantly outcompeted EcN mchDEF in this environment (Extended Data Fig. 8 ). Collectively, our data indicate that EcN produces microcins to limit growth of competing enterics in the inflamed gut.
We next investigated whether microcins could therapeutically treat an active enterobacterial infection by administering wild-type EcN or EcN mchDEF to mice previously infected with STm ( Fig. 4a ). Mice receiving wild-type EcN at days 2 and 5 after infection with STm showed substantially reduced levels of STm gut colonization (average 1,300-fold; up to 100,000-fold), inflammation and weight loss (Fig. 4b-d and Extended Data Fig. 9 ). This phenotype largely depended on microcins, as EcN mchDEF only minimally reduced STm intestinal burden (approximately 17-fold) and did not reduce inflammation or weight loss (Fig. 4b-d and Extended Data Fig. 9 ).
To understand the therapeutic phenotype better, we assayed the antibacterial activity of each microcin. Although both M and H47 microcins showed antibacterial activity against AIEC, only M was effective against STm and cEc (Extended Data Fig. 10a-c) ; the H47-resistance mechanism is unknown as neither strain carries the cognate immunity gene mchI. Accordingly, STm engineered to express mchI (STm pMchI) was not rescued in competition with wild-type EcN, whereas STm engineered to express mcmI (STm pMcmI) was rescued (Extended Data Fig. 10d, e) . Notably, the therapeutic administration of EcN only Supplementary Table 7 . Supplementary Table 7 . Letter reSeArCH minimally impaired colonization of the microcin-resistant STm pMcmI ( Fig. 4b and Extended Data Fig. 9 ). Furthermore, inflammation, weight loss and STm colonization were comparable when either EcN mchDEF or STm pMcmI were used in the therapeutic experiment ( Fig. 4b-d and Extended Data Fig. 9 ). Together, our data provide in vivo evidence that microcins mediate competition among Enterobacteriaceae in the inflamed gut. We show that the probiotic bacterium EcN employs microcins to compete with related species, colonize the inflamed gut, and therapeutically displace an enteric pathogen from its niche. The microcins produced by EcN target microbes that express particular siderophore receptors and do not severely affect the microbiota. Although siderophore-receptor mutants are resistant to microcins 14 (Extended Data Fig. 10f-h) , they are themselves attenuated in the inflamed intestine 24 and thus unlikely to be selected for. As microcins were particularly effective upon therapeutic EcN administration to pathogen-infected, inflamed mice, these or similar compounds (for example, siderophore-conjugated antibiotics 25 ) could conceivably be used as a targeted strategy to treat enterobacterial colitis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
Letter reSeArCH

MethOdS
Bacterial strains, culture conditions and chemicals. Strains of the probiotic E. coli Nissle 1917 (EcN; Mutaflor, DSM 6601), the mouse commensal E. coli (cEc), the adherent invasive E. coli (AIEC), and the pathogen S. enterica serovar Typhimurium (STm) used in this study are listed in Supplementary Table 3 . All plasmids used in this study are listed in Supplementary Table 4 . EcN was provided by Ardeypharm GmbH. The commensal E. coli strain was isolated from mice in our vivarium and does not appear to encode for known antibacterial exoproducts. The AIEC strain is a human isolate from a patient with Crohn's disease (isolate NRG857c O83:H1) 26 and was provided by A. Torres. The STm strain background we employed (IR715) is a fully virulent, nalidixic acid-resistant derivative of STm wild-type isolate ATCC 14028 and does not encode for known antibacterial exoproducts. All strains were routinely grown aerobically in Luria-Bertani (LB) broth (10 g l −1 tryptone, 5 g l −1 yeast extract, 10 g l −1 NaCl) or on LB agar plates at 37 °C. When indicated, antibiotics were added to the medium at the following concentrations: 0.03 mg ml −1 chloramphenicol (Cm); 0.1 mg ml −1 carbenicillin (Carb); 0.05 mg ml −1 kanamycin (Kan); 0.01 mg ml −1 tetracycline (Tet). For animal infections or bacterial administration, all strains were grown in LB medium aerobically at 37 °C overnight. For in vitro growth assays, strains were grown in iron-limiting conditions (nutrient broth supplemented with 0.2 mM 2,2′-dipyridyl dissolved in ethanol; Sigma) aerobically at 37 °C overnight. Restriction enzymes and Phusion High Fidelity DNA Polymerase were purchased from New England Biolabs. Oligonucleotides were synthesized by Fisher Scientific and are listed in Supplementary Tables 5 and 6 . Generation of bacterial mutants. Mutants in EcN and STm were constructed using the lambda red recombinase system 27 . In brief, primers (Supplementary Table 5 ) homologous to sequences flanking the 5′ and 3′ ends of the target regions were designed (H1 and H2 primers, respectively; Supplementary Table 5 ) and were used to replace the selected genes with a chloramphenicol-(derived from pKD3), kanamycin-(derived from pKD4) or tetracycline-resistance cassette ( Supplementary Table 4 ). Strain names for the mutants are listed in Supplementary  Table 3 . To confirm integration of the resistance cassette and deletion of the target, mutant strains and wild-type controls were each assayed using three PCR amplifications (5′ end, 3′ end, deleted target) to validate mutations. Primers (Supplementary Table 5 ) that flank the target sequence were used in conjunction with a common test primer (C1, C2, K1, K2 or primers for the tetRA cassette) to test for both new-junction fragments. Complementation studies. The mchDEF region was amplified from EcN genomic DNA using primers listed in Supplementary Table 5 . A region of 4,148 bp was amplified to ensure all regulatory elements were included. The PCR fragment was cloned into plasmid pCR-XL-TOPO using Zero Blunt TOPO PCR Cloning Kit (Invitrogen) according to the manufacturer's protocol, subcloned into the multiple cloning site of low-copy plasmid pWSK29, and confirmed by Sanger sequencing (Eton Bioscience). The mchDEF mcmI and mchDEF mchI constructs were amplified from EcN genomic DNA using primers listed in Supplementary Table 5 . PCR fragments of 4,321 bp (mchDEFmcmI), 4,000 bp (mchDEF) and 400 bp (mchI) were directly assembled with plasmid pWKS30 using the Gibson assembly method. In vitro growth assays. The role of EcN microcins against cEc, AIEC and STm was tested by an in vitro competitive growth assay in iron-rich and iron-limiting conditions. Strains were grown in nutrient broth supplemented with 0.2 mM 2,2′-dipyridyl (Sigma) aerobically at 37 °C overnight. Approximately 5 × 10 3 CFU ml −1 from an overnight culture were inoculated into 0.1 ml of tissue-culture medium (DMEM/F12 with 10% fetal bovine serum (FBS); Invitrogen), as previously described 23, 24 . When indicated, medium was prepared with 1 μ M ferric iron citrate (Sigma). Wild-type EcN or EcN mutants were inoculated in competition with wild-type STm, STm mutants, cEc, or AIEC. CFUs of each strain were enumerated by plating serial dilutions at 0, 5, 8, 11 and (for some assays) 16 h after inoculation. Mice. The Institutional Animal Care and Use Committee at the University of California, Irvine approved all mouse experiments. Eight-to-ten-week-old male and female C57BL/6 Slc11a1 + (also known as Nramp1) mice were bred and housed in a vivarium. For some experiments, mice were purchased from Jackson laboratory and, upon arrival, allowed to acclimate to the new environment for at least one week before the start of an experiment. All mice were housed under specific pathogen-free conditions. Mice were fed an irradiated 2920X Teklad diet (Envigo). For one experimental procedure, mice were fed an irradiated iron-rich diet (1% diet FeSO 4 2020, Teklad TD 160234; Envigo). Culturing faeces on MacConkey agar indicated that culturable enterobacteria were absent from our mice. Five to ten mice were used per experimental group, as indicated by the number of symbols in each figure panel. Group sizes were based on previous studies that detected a tenfold difference with statistical significance. For one experiment, ten-week-old Swiss Webster germ-free mice were used. Swiss Webster germ-free mice were maintained in sterile isolators and were fed a double-irradiated diet (Purina 5066, Charles River Rodent 18% Vac Pac). For this experimental procedure, three mice per experimental group were used (see figure panels). Mice were randomly grouped in cages of a maximum five animals per cage. Similar numbers of male and female mice were used in each experimental group. No blinding was performed, with the exception of histopathology. Dextran sulphate sodium-induced colitis mouse model. Drinking water was replaced with either filter-sterilized water (mock treatment) or with a filter-sterilized solution of 4% (w/v) dextran sulphate sodium (DSS; relative molecular mass 36,000-50,000; MP Biomedicals) in water as indicated. For DSS-treated mice, 3 days before the end of the experiment, drinking water was switched for 24 h to filter-sterilized water. Drinking water was then replaced with either filter-sterilized water (mock treatment) or with a filter-sterilized solution of 2% (w/v) DSS. At 4 days after the start of DSS treatment, animals were orally inoculated with a 1:1 ratio of 5 × 10 8 CFU of wild-type EcN and mutants in competition with cEc or AIEC strains (resuspended in 0.1 ml LB broth). Faecal material was collected each day after bacterial administration, resuspended in sterile PBS and the bacterial load was determined by plating serial tenfold dilutions on selective agar plates. Animals were euthanized 5 days after inoculation. Caecal tissue was collected and then flash-frozen in liquid nitrogen and stored at − 80 °C for later isolation of mRNA and protein. The caecal tip was fixed in 10% formalin for histopathology. Faecal material and caecal content were collected in sterile PBS and the bacterial load for the E. coli strains was determined by plating serial tenfold dilutions on selective agar plates. At some time points, a mouse did not produce faecal material, hence an n value is displayed for a given time point that is less than the experiment's indicated n value for that group. To differentiate EcN from other E. coli strains in biological samples, the strains were differentially marked with the low-copy number pACYomega (Cm) or pHP45omega (Carb) ( Supplementary Table 4 ), and markers were swapped in some experiments. Plasmids were stably maintained throughout the infection and similar colonies were counted in other differential media such as on MacConkey agar (not shown). When noted, the ratio of two strains in the faeces and caecal content was calculated by dividing the output ratio (EcN CFU/cEc or AIEC CFU) by the input ratio (EcN CFU/cEc or AIEC CFU). The competitive index was calculated for isogenic strains by dividing the output ratio (EcN wild-type CFU:mutant CFU) by the input ratio (EcN wild-type CFU:mutant CFU). S. Typhimurium-induced colitis. C57BL/6 Nramp1 + mice were treated with streptomycin (100 μ l of a 200 mg ml −1 solution in sterile water) one day before infection. The following day, mice were orally inoculated with 1 × 10 9 CFU of STm (resuspended in 0.1 ml LB broth) or with a 1:1 ratio of 5 × 10 8 CFU each of STm and wild-type EcN, or EcN mchDEF strain for competitive colonization experiments. For therapeutic administration of EcN after STm infection, C57BL/6 Nramp1 + mice were treated with streptomycin (100 μ l of a 200 mg ml −1 solution in sterile water) one day before STm infection. The following day, mice were orally inoculated with 1 × 10 9 CFU of STm. At days 2 and 5 after STm infection, mice were either mock-treated or treated with 1 × 10 9 CFU of wild-type EcN or EcN mchDEF. Faecal material was collected each day after bacterial administration and resuspended in sterile PBS. Bacterial load for STm and EcN strains was then determined by plating serial tenfold dilutions on selective agar plates. At some time points, a mouse did not produce faecal material, hence an n value is displayed for a given time point that is less than the experiment's indicated n value for that group. At day 7 following infection, mice were euthanized and a portion of the caecum was flash-frozen in liquid nitrogen then stored at − 80 °C for later isolation of mRNA and protein. The caecal tip was fixed in 10% formalin for histopathology. Bacteria in the faecal content were counted by plating serial tenfold dilutions on LB agar plates containing the appropriate antibiotics. To selectively identify STm from EcN strain in the faecal content, strains were differentially marked with the low-copy number pACYomega (Cm) or pHP45omega (Carb) plasmids. Plasmids were stably maintained throughout the infection and similar colonies were counted in other differential media such as MacConkey agar (not shown). When noted, the ratio of two strains was calculated by dividing the output ratio (EcN CFU/STm CFU) by the input ratio (EcN CFU/STm CFU). Extraction of bacterial DNA from faecal samples. Faecal samples were collected before DSS treatment (day − 4), at day 4 after DSS treatment (day 0; before inoculation of bacteria) and at day 5 after administration of commensal E. coli in competition with wild-type EcN or EcN mchDEF. Faeces were snap-frozen in liquid nitrogen, then DNA was later extracted using the QIAamp DNA Stool Kit (Qiagen) according to the manufacturer's instructions with modifications as previously described 18 . Because DSS interferes with PCR, we used the following procedure (developed by W. Zhu and S. Winter) to eliminate DSS from samples. Samples were eluted in 200 μ l of ultra-pure water and combined with 80 mg of KCl followed by vortexing for 2 min. The mixture was then incubated on ice for 30 min and centrifuged at 16,800g at 4 °C for 30 min. The supernatant was then transferred Letter reSeArCH to a new tube and 1/10 volume of 3 M NaAc (pH 5.2) was added. We then added 2.5 ml of pure ethanol to the mixture, vortexed and centrifuged at 16,800g at 4 °C for 30 min. The supernatant was removed and 1 ml of 70% ethanol was added to the pellet, vortexed and centrifuged at 16,800g for 5 min at room temperature. This wash step was repeated 3-4 times. The pellet was then air-dried at 55 °C and resuspended in 30 μ l of ultra-pure water. Analysis of microbiota. DNA extracted from faecal samples was amplified by a two-step PCR enrichment of 16S rDNA (V4 region) with primers 515F and 806R modified by addition of barcodes for multiplexing, then sequenced on an Illumina MiSeq system (UC Davis HMSB Facility). Sequences were processed and analysed by employing the QIIME pipeline v1.9.1 (ref. 28) with default settings, except as noted. In brief, paired-end sequences were joined, quality-filtered, reversecomplemented and chimaera-filtered (usearch61 option; RDP gold database); operational taxonomic units (OTUs) were picked (usearch61 option; enable_rev_ strand_match True) at 97% similarity; taxonomy was assigned (confidence 0.8) with the RDP classifier. Greengenes database v13_8 was used in the open-reference OTU picking workflow. Bacterial RNA extraction. A bacterial RNA mini-kit (Bio-Rad Aurum Total) was used to extract RNA from bacterial cultures. EcN strains were grown in nutrient broth supplemented with 0.2 mM 2,2′-dipyridyl aerobically at 37 °C overnight. Approximately 10 4 CFU ml −1 from an overnight culture were inoculated into 5 ml of tissue culture medium (DMEM/F12 plus 10% FBS, Invitrogen), as previously described 23, 24 . When indicated, iron citrate was added to the medium at a final concentration of 1 μ M. At 7 h post-inoculation, 2 × 10 9 CFU were used to extract RNA. An additional DNase treatment (Ambion) was done before the generation of cDNA with reverse transcription reagents (Roche). Quantitative real-time PCR. For analysis of gene expression by quantitative real-time PCR, total RNA was extracted from caecal tissue with TRI Reagent (Molecular Research Center). RNA from DSS-treated mice was further purified using the Dynabeads mRNA DIRECT Purification Kit (Life Technologies) according to manufacturer recommendations. Reverse-transcription reagents (Roche) were employed to generate cDNA from all RNA samples. Real-time PCR was performed using SYBR Green (Roche) and the Roche Lightcycler 480 Instrument II system (Roche). Data were analysed using the comparative − ∆∆ 2 C t method. Target gene transcription of each tissue sample was normalized to the respective levels of Actb mRNA (β -actin). For qPCR analysis of bacterial transcripts, transcription of mcmA and mchB was normalized to bacterial gapA mRNA levels. Data represent at least three independent experiments. DNA contamination was less than 1% for all bacterial amplicons, as determined by separate mock reactions lacking reverse transcriptase. All primers used are listed in Supplementary Table 6 . Histopathology analysis. Tissue samples were fixed in 10% formalin, processed according to standard procedures for paraffin embedding, sectioned at 5 mm, and stained with haematoxylin and eosin. The pathology score of caecal samples was determined by blinded examination of caecal sections from a board-certified pathologist using previously published methods 18 . Each section was evaluated for the presence of neutrophils, mononuclear infiltrate, submucosal oedema, surface erosions, inflammatory exudates, and cryptitis. Inflammatory changes were scored from 0 to 4 according to the following scale: 0, none; 1, low; 2, moderate; 3, high; 4, extreme. The inflammation score was calculated by adding up all scores obtained for each parameter and interpreted as follows: 0-2, within normal limit; 3-5, mild; 6-8, moderate; ≥ 8, severe. Statistical analysis of data. The experiments were not randomized. No statistical methods were used to predetermine sample size. Prism 6 and 7 software (GraphPad) was used for statistical analysis. Bacterial growth curves were analysed by unpaired Student's t-test. To compare bacterial CFUs in faeces and caecal content, mRNA expression, and eubacterial taxa present at greater than 0.5% relative abundance in at least one sample, we applied a non-parametric Mann-Whitney-Wilcoxon test. We chose this test because it can be applied to data with normal or unknown distribution. P-values for all statistical comparisons presented in the main text, figures and Extended Data are available in Supplementary Table 7 . Data availability. The data that support the findings of this study are available from the corresponding author upon request. Faecal microbiota 16S rRNA gene sequencing data were deposited in the European Nucleotide Archive under accession PRJEB15700. 
